Edition:
India

Deena Beasley

Trump nominates MD Anderson oncologist as U.S. FDA Commissioner

02 Nov 2019

U.S. President Donald Trump plans to nominate Dr. Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration, the White House said on Friday.

Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China

01 Nov 2019

LOS ANGELES Amgen Inc said on Thursday it will take a 20.5% stake in BeiGene Ltd in a deal to expand the California-based biotechnology company's presence in China, the world's second largest pharmaceutical market.

Amgen to take 20.5% stake in BeiGene to expand in China

01 Nov 2019

LOS ANGELES, Oct 31 Amgen Inc said on Thursday it will acquire a 20.5% stake in BeiGene Ltd in a deal that will enable the California-based biotechnology company to expand its presence in China, the world's second largest pharmaceutical market.

Amgen posts higher biosimilar sales, ends neuroscience program

30 Oct 2019

Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the quarterly results were ahead of Wall Street estimates.

Amgen third-quarter revenue falls 3%, biosimilar sales rise

30 Oct 2019

Oct 29 Amgen Inc on Tuesday said competition for older off-patent drugs sent third-quarter revenue down 3%, but share repurchases and biosimilar sales helped it achieve higher-than-expected profit, and the company raised its full-year outlook.

Mirati drug shrinks tumors in some cancer patients in early-stage trial

29 Oct 2019

An experimental drug from Mirati Therapeutics Inc that targets a specific genetic mutation significantly reduced tumor size in 40% of patients with advanced lung and colorectal cancer so far evaluated in a small, early-stage trial, researchers said on Monday.

Gilead third-quarter results in line, but Yescarta sales dip

25 Oct 2019

Gilead Sciences Inc on Thursday posted third-quarter results largely in line with Wall Street estimates, led by higher HIV drug sales, but sales of cancer cell therapy Yescarta fell slightly from the previous quarter.

UPDATE 1-Gilead third-quarter results in line, but Yescarta sales dip

25 Oct 2019

Oct 24 Gilead Sciences Inc on Thursday posted third-quarter results largely in line with Wall Street estimates, led by higher HIV drug sales, but sales of cancer cell therapy Yescarta fell slightly from the previous quarter.

Gilead posts third-quarter net loss, sales in line with Street estimates

25 Oct 2019

Oct 24 Gilead Sciences Inc on Thursday reported third-quarter results largely in line with Wall Street estimates, led by higher sales of its HIV drugs, but deal-related costs led to a net loss.

U.S. FDA approves Gilead's Descovy for HIV prevention

04 Oct 2019

The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's Descovy to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

World News